Thyroid cancerMaria E. Cabanillas(The University of Texas MD Anderson Cancer Center), David G. McFadden(The University of Texas Southwestern Medical Center), Cosimo Durante(Sapienza University of Rome)The LancetMay 29, 201610.1016/s0140-6736(16)30172-6Cited by 1,434Open AccessFull TextSaveCiteExport RISWatch citationsAbstractRelated PapersIntegrated Genomic Characterization of Papillary Thyroid CarcinomaNishant Agrawal, Rehan Akbani, Bülent Arman Aksoy et al.|Cell|2014|3.1kRevised American Thyroid Association Guidelines for the Management of Medullary Thyroid CarcinomaSamuel A. Wells, L. Sylvia, Henning Dralle et al.|Thyroid|2015|2.4kLenvatinib versus Placebo in Radioiodine-Refractory Thyroid CancerMartin Schlumberger, Makoto Tahara, Lori J. Wirth et al.|New England Journal of Medicine|2015|2kVemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 MutationsDavid M. Hyman, Igor Puzanov, Vivek Subbiah et al.|New England Journal of Medicine|2015|1.7kThe Prognostic Significance of Nodal Metastases from Papillary Thyroid Carcinoma Can Be Stratified Based on the Size and Number of Metastatic Lymph Nodes, as Well as the Presence of Extranodal ExtensionGregory W. Randolph, Quan‐Yang Duh, Keith S. Heller et al.|Thyroid|2012|858